Background Asbestos is a carcinogen linked to malignant mesothelioma (MM) and lung cancer. Some gene aberrations related to asbestos exposure are recognized, but many associated mutations remain obscure. We performed exome sequencing to determine the association of previously known mutations (driver gene mutations) with asbestos and to identify novel mutations related to asbestos exposure in lung adenocarcinoma (LAC) and MM. Methods Exome sequencing was performed on DNA from 47 tumor tissues of MM (21) and LAC (26) patients, 27 of whom had been asbestos-exposed (18 MM, 9 LAC). In addition, 9 normal lung/blood samples of LAC were sequenced. Novel mutations identified from exome data were validated by amplicon-based deep sequencing. Driver gene mutations in BRAF, EGFR, ERBB2, HRAS, KRAS, MET, NRAS, PIK3CA, STK11, and ephrin receptor genes (EPHA1-8, 10 and EPHB1-4, 6) were studied for both LAC and MM, and in BAP1, CUL1, CDKN2A, and NF2 for MM. Results In asbestos-exposed MM patients, previously non-described NF2 frameshift mutation (one) and BAP1 mutations (four) were detected. Exome data mining revealed some genes potentially associated with asbestos exposure, such as MRPL1 and SDK1. BAP1 and COPG1 mutations were seen exclusively in MM. Pathogenic KRAS mutations were common in LAC patients (42 %), both in non-exposed (n = 5) and exposed patients (n = 6). Pathogenic BRAF mutations were found in two LACs. Conclusion BAP1 mutations occurred in asbestos-exposed MM. MRPL1, SDK1, SEMA5B, and INPP4A could possibly serve as candidate genes for alterations associated with asbestos exposure. KRAS mutations in LAC were not associated with asbestos exposure.
Introduction
Asbestos, which are naturally occurring mineral silicate fibers, are the most important work-related carcinogens being responsible for lung and mesothelial malignancies [1] . Asbestos fibers are inhaled into the deep parts of the lungs, where the fibers can penetrate the pleural space and encounter mesothelial cells [2] . MM has a long latency after the exposure. Thus, despite prohibitions on the use of asbestos in many industrialized countries, new MM cases still represent a major health problem.
Complex chromosomal abnormalities, molecular genetic and epigenetic (methylation, acetylation) alterations, as well as miRNA deregulations are typical features encountered in MM [3] [4] [5] . There are some other commonly seen alterations, e.g., either deletions or downregulation in NF2, CDKN2A and mutations in BAP1, and upregulation of EGFR, VEGF, BCL2, and MET [5] . Recent studies have indicated that patients with germline BAP1 mutations are more prone to develop asbestos-induced malignant pleural mesothelioma [6, 7] . At present, very little is known about the genomic changes that are associated with asbestos exposure. There is one early cytogenetic study, which did reveal that chromosomal deletions and translocations in the short arm of chromosome 1 and partial or total losses of chromosomes 1 and 4 were significantly associated with a high asbestos fiber count in MM [3] .
Occupational asbestos exposure is an important risk factor for lung cancer and all fiber types increase the lung cancer risk [1] . Asbestos in combination with tobacco smoke acts as a co-carcinogen and has activities with the characteristics of both multiplicative and additive factors [1, 8, 9] . The genetic alterations occurring in asbestos-related lung cancer appear to be different from those encountered in tobacco smokerelated lung cancer [9] [10] [11] . Gene expression, miRNA, and copy number alteration (CNA) studies have provided evidence that there are differences in genomic alterations between asbestos-exposed and non-exposed lung tumors [12] [13] [14] . However, the specific mutations occurring in asbestos-related lung cancer still remain obscure.
We performed exome sequencing with the aim of studying recurrent novel somatic mutations in asbestosexposed lung adenocarcinoma (LAC) and MM, as they are the largest groups of tumor types related to asbestos exposure, and also to investigate known driver genes for probable pathogenic mutations in these patients.
Materials and Methods

Patients
We selected 26 LAC (9 asbestos-exposed) and 21 epithelioid MM (18 asbestos-exposed) tumor samples for exome sequencing based on asbestos fiber counts (Table 1) . Additionally, normal tissue samples (leucocytes or normal lung tissue) from 9 of the LAC patients (3 asbestos-exposed) were also examined. All patients were of Finnish origin and diagnosed and operated in the Hospital District of Helsinki and Uusimaa (HUS), Finland. All samples were collected before any treatments. All MM samples were formalin-fixed, paraffin-embedded (FFPE) tumor tissues, and all tumorous LAC material was from fresh frozen (FF) samples with average tumor content of 60 % (range 10-97 %, 45/47 samples with more than 25 %). The asbestos fiber content of lung tissue in patients not considered as being exposed was set as follows: less than 0.2 9 10 6 /g (of dry lung tissue) and 1.0 9 10 6 /g for MM and LAC, respectively. In the asbestosexposed group, lung samples contained fibers more than 1.0 9 10 6 /g and 2.0 9 10 6 /g in MM and LAC, respectively. The actual asbestos fiber ranges are listed in Table 1 . Ethical permissions for this study were obtained.
Asbestos Fiber Measurement
The asbestos fiber count was performed on normal lung tissue samples, obtained during the operation from the surrounding normal lung tissue, by scanning electron microscopy (SEM) on LAC specimens [15] and by transmission electron microscopy (TEM) on MM samples. The assessment of asbestos fibers in lung tissue was conducted at the Finnish Institute of Occupational Health, Helsinki, according to the standardized protocol [16] .
DNA Extraction
DNA was extracted from both FFPE and FF samples by the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. The protocol for FFPE tissue samples included the modifications described in our previous study [17] . The Qubit Ò fluorometer (Life Technologies, Carlsbad, CA) was used to quantify the isolated DNA.
Exome Sequencing
Exome libraries were prepared from 1-3 lg of each DNA according to NimbleGen SeqCap EZ Exome 2.0 Library SR User's Guide. Sequencing was performed on Illumina's HiSeq sequencer (Illumina, Inc., San Diego, CA, USA). Detailed protocol is described in supplemental file 1.
Validation of Novel Mutations by Amplicon Sequencing
Novel variations seen in the exome sequencing were validated and checked for their somatic/germline origin by PCR amplification of the region of interest, performed on DNA from paired tumor and normal adjacent lung tissue. PCR amplicons were sequenced on Illumina MiSeq instrument (Illumina, Inc., San Diego, CA, USA). A detailed protocol is described in supplemental file 2.
Primary Data Analysis
Primary analysis for exome data was performed by the variant-calling pipeline (VCP) developed in the Finnish Institute of Molecular Medicine (FIMM) [18] . VCP uses commonly used sequencing data analysis software combined with their own in-house algorithms. Prior to alignment, the overlapping paired reads were merged into single longer reads using SeqPrep [19] . Exome sequencing data were processed further for quality.
Data obtained from amplicon sequencing were processed with an in-house amplicon pipeline that similarly to VCP utilizes common NGS software combined with inhouse algorithms. Bowtie 2 [20] was used for the read alignment to the reference genome of GRCh37 with Ensemble release 70 annotation, SAMtools [21] , and BCFtools [22] for variant calling and GATK IndelRealigner [23] for indel calling.
Secondary Data Analysis
Exome Sequencing
For novel somatic mutations associated with asbestos exposure, all single nucleotide variants (SNVs) and small insertion and deletion variants (indels) were combined. We selected novel mutations occurring in the protein coding regions of genes and removed all those which had been recorded in the 1000 Human Genomes project or the NCBI dbSNP database (build 137) or which were present in the exomes of paired normal samples. Two in silico analysis tools, PROVEAN/SIFT, were used for prediction of the effect of the missense variants on the produced protein. Of those, we selected mutations resulting in indel, nonsense, or deleterious/damaging missense mutations, as predicted in in silico by PROVEAN or SIFT analyses [24, 25] . Of those, we selected those mutations or genes mutated exclusively in asbestos-exposed patient samples. We analyzed the exome data according to the most frequently mutated chromosomal positions and the genes involved. Due to the small set of samples, no statistical significance was found, and thus, we set the threshold for recurrent variants/genes as only those occurring in three or more exposed patients. All results obtained by previously described workflow and thresholds were checked by the Integrative Genomics Viewer (IGV) for visualization [26] and NCBI dbSNP (build 142) to remove variants reported in a newly built database.
Further, we selected the genes that are known to be altered in MM and/or LAC according to reports in the literature. Driver gene mutations in BRAF, EGFR, ERBB2, HRAS, KRAS, MET, NRAS, PIK3CA, and STK11 were studied for both LAC and MM and in BAP1, CUL1, CDKN2A, and NF2 for MM. Moreover, for MM and LAC, we selected ephrin receptor genes EPHA1-8, 10 and EPHB1-4, 6 based on our previous study of frequently mutated receptor tyrosine kinases (RTKs) in lung cancer [27] . From those, we selected the variants occurring in coding regions and causing nonsense, missense, and indel mutation and occurring less than 2 % in the 1000 Human Genomes project. NCBI dbSNP build 142 was used for studying SNPs. We performed PROVEAN/SIFT in silico analyses for rare variants and selected those missense variants with deleterious effects predicted by either algorithm [24, 25] .
Validation by Deep Sequencing
A bioinformatics pipeline was used for analyzing the data. When a frequency of variant base was 0.5 % of all reads covering a given position, a variant was called. The base frequency was compared to the quality value of the corresponding base. All variants with a frequency ratio of minimum of 0.7 were considered to be true sequence variants. The depth of those variant sequences varied between 212 and 48217, and the frequency ratio was at least 0.83.
Results
Exome sequencing analysis of 21 MM and 26 LAC (9 with paired normal sample) cases resulted in 1504431 variants occurring in the coding region. After removing all variants found in the 1000 Human Genomes projects and/or described in NCBI dbSNP (build 137), and then removing all variants found in normal samples and those predicted as neutral by PROVEAN, a number of variants left were 9448. All variants found in non-exposed group of samples were removed, leaving 3048 variants that were found to occur exclusively in asbestos-exposed samples. In order to detect recurrent mutations associated with asbestos exposures, we selected only those mutations that occurred in three or more cases. For exome sequencing, mean average target coverage was 38.1 (range 12.8-54.1). Mean target coverage was on an average of 36.7 (range 12.8-54.0) in FFPE samples and 39.0 (range 20.3-54.1) in FF samples.
Asbestos-Associated Novel Mutations
We found a recurrent novel mutation in MRPL1 (Tyr87-Cys), which was present in three asbestos-exposed patients.
Mutations were predicted as deleterious/damaging by SIFT/PROVEAN analysis and they were not seen in nonexposed LAC or MM samples or paired normal LAC samples. The other genes most commonly (with predicted deleterious protein product) and exclusively mutated in asbestos-exposed patients were BAP1, COPG1, INPP4A, MBD1, SDK1, SEMA5B, TTLL6, and XAB2 (Table 2) ; of those, mutations in BAP1 and COPG1 occurred only in MM patients.
Validation of Novel Mutations by Amplicon Sequencing
Deep sequencing revealed mutations in BAP1 as somatic, i.e., those were seen in tumor material but not in normal paired material from the same patient (Table 2 ; Fig. 1 ). From one patient, normal material was not available, but this mutation was reproducible in the tumor sample. In addition, the SDK1 mutation (Gln963Ter) was validated as being somatic (Fig. 1) . Moreover, mutations in the following genes were validated in the tumor material which was the only sample material available from those patients: COPG1 (Cys230Arg), SEMA5B (Thr1040Pro), INPP4A (Lys954Arg), and TTLL6 (Glu56 fs). The MRPL1 (Tyr87Cys) mutation was not seen in one paired normal sample, which supports the somatic nature of the recurrent MRPL1 mutation.
Association of Driver Gene Mutations with Asbestos Exposure
In LAC, a total of 42 % (11/26) harbored the KRAS mutation (codons 12, 13 and 61). KRAS mutations occurred both in asbestos-exposed (n = 6) and non-exposed (n = 5) individuals. BRAF mutations (codon 469 and 601) were found in two non-exposed patients. We did not detect any of the known activating EGFR mutations. One of the EGFR mutations (His870Arg) detected has been reported previously (COSM33725). All these KRAS, EGFR, and BRAF mutations were mutually exclusive. No possible deleterious missense, nonsense, or indel alterations in coding regions were detected in NRAS, HRAS, and PIK3CA.
In MM, a BAP1 mutation was found in four patients, all asbestos-exposed. A single nucleotide deletion in NF2 was detected in one asbestos-exposed patient. One novel EGFR mutation (Pro243Ala) was seen in one asbestos-exposed patient. No likely deleterious missense, nonsense, or indel alterations in coding regions were observed in BRAF, CUL1, CDKN2A, ERBB2, HRAS, KRAS, MET, NRAS, and PIK3CA. The results are presented in Table 3 .
Ephrin Receptor Mutations
The ephrin receptor mutations found in this study are shown in Table 4 . These were present in both asbestosexposed and non-exposed patients. Some rare SNPs of EPHA2 (rs11543934) and EPHA3 (rs34437982) were detected in our previous study [27] . No normal paired material was sequenced from those patients, so that the somatic nature of those SNPs remains obscure. Table 2 The most recurrently mutated genes in asbestos-exposed LAC and MM patients detected by exome sequencing The exome data mining identified genes BAP1, COPG1, INPP4A, MBD1, SDK1, SEMA5B, TTLL6, and XAB2 as being frequently mutated (at least in three patients) and exclusively in asbestos-exposed patients. After validation with amplicon-based deep sequencing, mutations in BAP1 and one mutation in SDK1 (Gln963Ter) could be validated reliably as being somatic. Unfortunately due to the lack of normal tissue and deep-sequencing challenges, somatic status of other candidate mutations remains elusive. BAP1 and COPG1 were the most frequently mutated genes seen exclusively in MM; a fact is in line with previous studies reporting BAP1 mutations in MM. All of the detected BAP1 mutations occurred in the region coding ubiquitin carboxyl hydrolase (UCH) site of the protein, which is known to be frequently mutated in MM or immediately after that region (five amino acids upstream) [28] . Nonetheless, none of these mutations have been reported previously in MM, although Phe170Cys has been found in kidney (COSM480289). Sporadic, somatic mutations have been found in 20 % of MM [28, 29] , and in COSMIC database, the mutation frequency of BAP1 in MM is 32 %, which are in accordance with our finding. A recent study showed BAP1 mutations in malignant pleural mesothelioma to be more common in smokers [29] . In the present study, three out of four BAP1 mutations were found in never-smokers, and one former smoker harbored this mutation.
There are no previous reports of COPG1 mutations in mesothelioma. COPG1 is a subunit of a coatomer protein complex that is involved in the COPI coat of vesicles during protein transport in the secretory pathway [30] . Little is known about the role of COPI coat vesicles in tumorigenesis or carcinogenesis, and very few somatic mutations in COPG have been described in COSMIC. An elevated expression of COPA, the alpha subunit of coatomer, has been reported in mesothelioma cell lines and COPA knockdown has been associated with a suppression of tumor growth and with the induction of apoptosis [31] . Since COPG1 and COPA are both part of the coatomer protein complex, our finding suggests that the coatomer protein complex might play an important role in MM.
In mesothelioma, it is very difficult to obtain asbestosnon-exposed cases and it is challenging to find sufficient numbers of these rare cases for mutation analyses with adequate statistical power. So, although all of the BAP1 and COPG1 mutations occurred in asbestos-exposed MM patients, it is not possible to conclude their exclusive association with asbestos exposure.
Our exome sequencing revealed a novel recurrent mutation in MRPL1 seen only in asbestos-exposed MM and LAC. MRPL1 is involved in protein synthesis within mitochondria. MRPL1 is a nuclear gene encoding the 39S subunit of the mitochondrial ribosome. The mutation found in the present study has not been described previously, but another somatic missense mutation in MRPL1 has been described in two small-cell lung cancers (COSM325848, COSM317641). Furthermore, some mutations have been reported in other cancers, such as in colorectal carcinoma tumors (COSMIC). The possible role of MRPL1 mutations in tumor biology is still not well understood; we can only speculate that it might be related to aberrant translation of mt-mRNAs derived from all 13 mitochondrial genes, which could affect cell metabolism. In particular, any interference with the production of ROS species is intriguing in asbestos-related cancer. Mutations in mtrRNA genes are probably the most important group for pathogenic variations in mitochondria, but confirmation of pathogenicity remains difficult [32] . Our data showed INPP4A, SDK1, and SEMA5B as frequently mutated genes in asbestos-related LAC and MM. INPP4A and SDK1 are related to oxidative stress. INPP4A dephosphorylates molecules, which function as second messengers and are important regulators in many signaling pathways. For example, INPP4A is a negative regulator of PI-3/Akt signaling, the dysfunction of which has been reported in many cancerous tissues [33] , and its activation can induce oxidative stress [34] . INPP4A has been identified as an asthma candidate gene, and its downregulation has been described in mice with allergic inflamed lungs [35] .
SDK1 is an adhesion molecule, which is activated by cellular stress especially in conditions with the reactive oxygen species. In starved cancer cells, SDK1 is expressed at high levels [36] . Intriguingly, a recent GWAS study showed the SDK1 gene and the region around the gene to be associated with the risk of malignant mesothelioma in Italian and Australian asbestos-exposed patients [37] . In our study, one somatic SDK1 mutation was found in an asbestos-exposed LAC patient, which may suggest that SDK1 may be associated with asbestos exposure, not only in MM but also in other asbestos-related lung malignancies.
SEMA5B belongs to the family of semaphorins. Somatic mutations in SEMA5B have been reported previously, but only three of them in lung tumors (COSM3944760, COSM326437, COSM3944757). In the GWAS study of esophageal cancer patients, SEMA5B was implicated as being a candidate gene at one susceptibility locus [38] .
Association of Driver Gene Mutations to Asbestos Exposure
We found pathogenic KRAS mutations (codons 12, 13 and 61) in 42 % of both asbestos-exposed and non-exposed LAC patients, suggesting that these mutations are not linked to exposure to asbestos. The mutation frequency is higher than reported in smokers (34 %) [39] , which might be due to the fact that a majority of our patients had heavy smoking history (median pack years 36), and also due to relatively smaller number of cases. One KRAS (Gly12Asp) positive patient harbored a concomitant STK11 (Glu293-Ter) mutation. Similar concomitant KRAS/STK11 mutations were recently reported in an adrenal metastasis from an LAC patient [40] . The BRAF mutations were found in two LAC patients and one of these patients harbored also STK11 mutation. None of the activating EGFR mutations were detected, which we believe might be due to the fact that nearly all our LAC patients had a history of smoking [39, 41] . EGFR mutation (His870Arg) was found in a case without smoking history. Two MET mutations were detected, both occurring in non-exposed patients with smoking history. Both mutations have been reported in lung tumor in COSMIC. There is clinical interest for MET mutations, but [24, 25] d Found in our previous study [27] Lung (2016) 194:125-135 133 no clear clinical relevance has been defined as yet, as the right biomarkers for anti-MET therapy remain obscure [42] . Mutations in ephrin receptor genes were seen in both asbestos-exposed and non-exposed patients. We also detected two rare variants that had been observed also in our previous study [27] . We found that ephrin receptors were not only recurrently mutated in LAC but also in MM, especially EPHB1 (with three mutations). However, their somatic status still remains elusive.
By conducting a detailed study of exomes from asbestos-exposed and non-exposed LAC and MM patients, we were able to identify mutations that were seen only in the exposed group. While mutations in BAP1 have been reported previously, the identification of novel recurrent mutations/mutated genes is important discoveries and can aid in future studies of asbestos-associated biomarkers. Mutations in known driver genes, such as KRAS and BRAF mutations, are not associated with asbestos exposure and were detected in lung cancer, as may be expected. Mutations in both of these driver genes showed a putative association with smoking but not with asbestos.
